Citation, DOI, disclosures and article data
At the time the article was created Matt A. Morgan had no recorded disclosures.View Matt A. Morgan's current disclosures
linear, non-ionic molecule
100% renally excreted
T1 relaxivity at 1.5 tesla: 4.0-4.6
concentration: 0.5 mmol/mL
recommended dosage: 0.1 mmol/kg
As an extracellular contrast agent, gadodiamide can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.
There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (OptiMARK) are contraindicated in patients with acute kidney injury or with chronic, severe kidney disease 2.